Updated Software Solutions Offer Increased Productivity and Data Confidence
Thermo Fisher Scientific Inc. has released new software to scientists in biopharmaceutical, proteomics, and small molecule settings to enable more comprehensive analysis of their data. The latest software updates bring new features that enable researchers to extract more information from their new and existing data, streamline data interpretation, and standardize reporting with increased ease of use.
“It’s essential that we continue to develop our software platforms to meet the increasing data analysis needs of our customers, expanding analytical capabilities and providing greater biological insights,” said August Specht, vice president, global research and development, chromatography and mass spectrometry, Thermo Fisher Scientific. “Thanks to the latest upgrades to our software suites, we can give scientists access to the newest technologies and built-for-purpose platforms to quickly and confidently turn data into meaningful results.”
Thermo Fisher Scientific is showcasing these latest software releases during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022 in Booth 400 at the Minneapolis Convention Center, Minneapolis, Minnesota and at the Hilton Minneapolis Grand Ballrooms E, F, G.
A complete solution for confident and streamlined biotherapeutic characterization
The newest Thermo Scientific BioPharma Finder 5.1 software offers a complete solution for oligonucleotide analysis and biotherapeutic characterization workflows, providing increased confidence in results by comprehensively characterizing mass spectrometry data using advanced algorithms. Oligonucleotide-based biotherapeutics present unique challenges for characterization due to their complexity. The new software provides an enhanced suite of built-for-purpose tools to overcome these challenges and meet the needs of this rapidly growing field, quickly and confidently turning complex data into meaningful results. Improvements to the kinetic prediction model for oligonucleotides enable more confident prediction and matching. Improved data review tools and tables offer streamlined review and results reporting of complex oligonucleotide data sets.
Redefining proteomics research capabilities by leveraging artificial intelligence
Proteomics scientists can now benefit from the newest Thermo Scientific Proteome Discoverer 3.0 software in combination with the CHIMERYS intelligent search algorithm by MSAID, leveraging artificial intelligence to more fully interpret data generated by Thermo Scientific Orbitrap mass spectrometers. This innovative approach substantially increases the number of unique peptide identifications, improves protein coverage and quantitation capabilities, and enables scientists to discover more in their data. The new intelligent search algorithm also facilitates higher throughput analysis and wide-isolation window data-dependent acquisition for synergistic performance enhancements. This deeper mining of data expands the ways in which proteomics scientists can acquire and apply their data.
Improving untargeted small molecule workflows with new peak detection and quality algorithms
Small molecule researchers can now leverage a faster and more sensitive peak detection algorithm with the newest Thermo Scientific Compound Discoverer 3.3 software to detect more compounds in less time. Filtering large data sets down to relevant compounds is now easier than ever by using the new peak quality functionality to streamline data processing and review. Improve confidence in compound annotations through MSn spectral tree search capabilities in tandem with the Thermo Scientific mzCloud spectral library to address the most challenging unknown compounds. Compound Discoverer 3.3 software, which has been optimized for processing large datasets and detecting low-abundance compounds, will support scientists in metabolomics, pharmaceutical, environmental, food safety, clinical, and forensics applications to acquire the results they need to drive science forward.